k8凯发(中国)天生赢家·一触即发

May 13^th, 2022      Shanghai, China

Impact Therapeutics announced that Dr. Timothy Yap joined Scientific Advisory Board of the company.

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center Houston, TX, USA. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research (NIHR) BRC Clinician Scientist at The Institute of Cancer Research, London, UK.

Dr. Yap gained his BSc degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr. Yap completed an Oncology Clinical Fellowship in the Phase I Drug Development Unit at the Royal Marsden Hospital, London, UK, before completing a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics at The Institute of Cancer Research, London, UK, under a Cancer Research UK Fellowship. He completed his specialist training in medical oncology at the Royal Marsden Hospital and was awarded a NIHR Academic Clinical Lectureship in Medical Oncology. He was then appointed as Consultant Medical Oncologist and NIHR Biomedical Research Centre Clinician Scientist jointly in the Phase I Drug Development Unit, Lung Cancer Unit and Cancer Biomarkers Laboratory at the Royal Marsden Hospital and The Institute of Cancer Research in London, UK, before subsequently moving to his current position at the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. He is and/or has been the Principal Investigator for multiple clinical trials and translational studies evalsuating novel strategies for targeting the DNA damage response (DDR) in cancer, including PARP, ATR, ATM, DNA-PK, WEE1, POLQ, USP1 and RAD51 inhibitors as monotherapy and in rational combinations, as well as the development of novel immunotherapeutics.

Dr. Timothy Yap is the fifth member of Impact Scientific Advisory Board.  The other four members are Dr. Douglas Hanahan, Dr. Robert Weinberg, Dr. Alan D' Andrea and Dr. Andrew Zhu.  Impact CEO Dr. Jun Bao said, “It’s a great honor to have Dr. Timothy Yap on our Scientific Advisory Board. Tim is the world leading clinical expert in DDR field. His experiences in clinical studies of several DDR agents as well as his insights in DDR area will help Impact greatly in developing our pipeline products. We look forward to working together with Tim and really making an impact on cancer treatment.”

About Impact Therapeutics

Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, and dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled a most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and is expanding to other novel synthetic lethality targets to broaden its pipeline. Impact has been invested by recognized venture capital firms including Lilly Asia Ventures.